Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

The layoffs had decimated the workforce that processes Freedom of Information Act requests across FDA centers.

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

It is still being sold under emergency use authorization — unlike mRNA vaccines made by Pfizer and Moderna that have earned ...

There's new uncertainty about updated COVID-19 shots this fall after the Trump administration's handling of a shot from ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...

and Pfizer. According to TipRanks, Breen has an average return of 0.8% and a 41.18% success rate on recommended stocks. Currently, the analyst consensus on Moderna is a Hold with an average price ...

with sales of GSK’s Arexvy declining 70% year over year in the last three months of 2024 and Pfizer’s Abrysvo revenues dropping 62% during the same period. Moderna’s newer entry, mRESVIA ...

Right now, it is only approved under emergency use. That’s different from the mRNA vaccines from Pfizer and Moderna, which ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...